TARGRETIN 75mg soft capsules EISAI ORIGINAL MEDICINE
Chemical substance: bexarotene
ATC code: L01XX25 • Antineoplastic and immunomodulating agents | Other antineoplastic agents
Active substance
Results for the substance bexarotene
1 result
About this active substance
Bexarotene is a medication used in the treatment of cutaneous T-cell lymphoma (CTCL), a rare form of cancer that affects the skin. It belongs to a class of drugs called retinoids, which are derivatives of vitamin A. Bexarotene works by regulating cell growth and differentiation, helping to reduce the symptoms of the disease.
The medication is available in oral capsule form and is typically used in patients who have not responded to other treatments. The dosage and duration of treatment are determined by the doctor based on the patient's condition and response to therapy. It is important for patients to strictly follow the doctor's instructions to achieve the best results.
Common side effects of bexarotene include hypothyroidism, increased blood lipid levels, fatigue, and skin rashes. The drug may also cause photosensitivity, so patients are advised to avoid prolonged sun exposure.
Bexarotene is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Before starting treatment, patients should inform their doctor about all medications they are taking to avoid drug interactions.
The medication is available in oral capsule form and is typically used in patients who have not responded to other treatments. The dosage and duration of treatment are determined by the doctor based on the patient's condition and response to therapy. It is important for patients to strictly follow the doctor's instructions to achieve the best results.
Common side effects of bexarotene include hypothyroidism, increased blood lipid levels, fatigue, and skin rashes. The drug may also cause photosensitivity, so patients are advised to avoid prolonged sun exposure.
Bexarotene is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Before starting treatment, patients should inform their doctor about all medications they are taking to avoid drug interactions.